IL159840A0 - Use of 2-alkoxyphenylsubstituted imidazotriazinones - Google Patents

Use of 2-alkoxyphenylsubstituted imidazotriazinones

Info

Publication number
IL159840A0
IL159840A0 IL15984002A IL15984002A IL159840A0 IL 159840 A0 IL159840 A0 IL 159840A0 IL 15984002 A IL15984002 A IL 15984002A IL 15984002 A IL15984002 A IL 15984002A IL 159840 A0 IL159840 A0 IL 159840A0
Authority
IL
Israel
Prior art keywords
upto
alkoxycarbonyl
cooh
alkyl
diseases
Prior art date
Application number
IL15984002A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of IL159840A0 publication Critical patent/IL159840A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IL15984002A 2001-07-23 2002-07-17 Use of 2-alkoxyphenylsubstituted imidazotriazinones IL159840A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10135815A DE10135815A1 (de) 2001-07-23 2001-07-23 Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
PCT/EP2002/007959 WO2003011262A2 (de) 2001-07-23 2002-07-17 Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen

Publications (1)

Publication Number Publication Date
IL159840A0 true IL159840A0 (en) 2004-06-20

Family

ID=7692784

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15984002A IL159840A0 (en) 2001-07-23 2002-07-17 Use of 2-alkoxyphenylsubstituted imidazotriazinones

Country Status (28)

Country Link
US (3) US6930108B2 (ja)
EP (2) EP1733728A3 (ja)
JP (1) JP2005504751A (ja)
KR (1) KR20040032865A (ja)
CN (1) CN1649593A (ja)
AT (1) ATE442144T1 (ja)
AU (1) AU2002319296B2 (ja)
BG (1) BG108533A (ja)
BR (1) BR0211359A (ja)
CA (1) CA2454414A1 (ja)
CO (1) CO5560536A2 (ja)
CZ (1) CZ2004128A3 (ja)
DE (2) DE10135815A1 (ja)
EC (1) ECSP044956A (ja)
EE (1) EE200400056A (ja)
ES (1) ES2330418T3 (ja)
HR (1) HRP20040065A2 (ja)
HU (1) HUP0500734A3 (ja)
IL (1) IL159840A0 (ja)
MA (1) MA26128A1 (ja)
MX (1) MXPA04000675A (ja)
NO (1) NO20040294L (ja)
NZ (1) NZ530703A (ja)
PL (1) PL373392A1 (ja)
RU (1) RU2321406C9 (ja)
SK (1) SK442004A3 (ja)
UA (1) UA76997C2 (ja)
WO (1) WO2003011262A2 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
PT2366393E (pt) 2005-04-19 2013-10-04 Takeda Gmbh Roflumilaste para o tratamento da hipertensão pulmonar
JP5540454B2 (ja) * 2009-12-30 2014-07-02 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ阻害剤
AT512084A1 (de) * 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
MX2019007135A (es) * 2016-12-16 2019-11-18 Cystic Fibrosis Found Therapeutics Inc Derivados de heteroarilo biciclico como potenciadores de cftr.
CN113461694A (zh) * 2021-08-05 2021-10-01 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4479210A (en) * 1982-11-19 1984-10-23 U.S. Philips Corporation Record-disc player
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
DE69622031T2 (de) * 1995-04-10 2002-12-12 Fujisawa Pharmaceutical Co INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
US6166219A (en) * 1995-12-28 2000-12-26 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
DE19812462A1 (de) * 1998-03-23 1999-09-30 Bayer Ag 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
CZ298826B6 (cs) * 1997-12-12 2008-02-20 Cell Pathways, Inc. Deriváty n-benzyl-3-indenylacetamidu pro lécbu novotvaru
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
FR2792634B1 (fr) * 1999-04-20 2001-06-01 Synthelabo Derives de 2-alcoxy-cyclobutene-3,4-dione leur preparation et leur application en therapeutique
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
WO2001032170A1 (en) * 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
DE19943815A1 (de) * 1999-09-14 2001-03-15 Merck Patent Gmbh Verwendung von Thienopyrimidinen
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1220672B1 (de) * 1999-10-12 2006-10-04 Lilly Icos LLC Arzneimittel zur behandlung von neuropathien
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US6774128B2 (en) * 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
EP1278522B1 (en) * 2000-04-19 2006-10-25 Lilly Icos LLC Pde-v inhibitors for treatment of parkinson's disease
CA2419033A1 (en) * 2000-08-11 2002-02-21 Earl Michael Gibbs Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
WO2002019213A2 (en) * 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
DE10107639A1 (de) 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DK1392314T3 (da) * 2001-05-09 2007-03-12 Bayer Healthcare Ag Hidtil ukendt anvendelse af 2-[2-ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-on
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
EP1492567A1 (en) * 2002-03-06 2005-01-05 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics in cancer treatment

Also Published As

Publication number Publication date
RU2004105265A (ru) 2005-04-20
DE10135815A1 (de) 2003-02-06
CN1649593A (zh) 2005-08-03
US20040235838A1 (en) 2004-11-25
HUP0500734A3 (en) 2005-12-28
US7276504B2 (en) 2007-10-02
EP1733728A2 (de) 2006-12-20
CO5560536A2 (es) 2005-09-30
WO2003011262A3 (de) 2004-05-27
BG108533A (bg) 2005-02-28
NZ530703A (en) 2006-06-30
MA26128A1 (fr) 2004-04-01
EE200400056A (et) 2004-04-15
US20080085897A1 (en) 2008-04-10
SK442004A3 (en) 2004-06-08
CZ2004128A3 (cs) 2004-08-18
HUP0500734A2 (hu) 2005-11-28
ECSP044956A (es) 2004-02-26
DE50213840D1 (de) 2009-10-22
ATE442144T1 (de) 2009-09-15
BR0211359A (pt) 2004-07-13
KR20040032865A (ko) 2004-04-17
MXPA04000675A (es) 2004-11-22
CA2454414A1 (en) 2003-02-13
AU2002319296B2 (en) 2007-08-30
EP1474150A2 (de) 2004-11-10
PL373392A1 (en) 2005-08-22
US6930108B2 (en) 2005-08-16
RU2321406C9 (ru) 2009-03-27
HRP20040065A2 (en) 2004-12-31
EP1474150B1 (de) 2009-09-09
ES2330418T3 (es) 2009-12-10
WO2003011262A2 (de) 2003-02-13
EP1733728A3 (de) 2007-03-21
UA76997C2 (en) 2006-10-16
US20050234022A1 (en) 2005-10-20
JP2005504751A (ja) 2005-02-17
NO20040294L (no) 2004-01-22
RU2321406C2 (ru) 2008-04-10

Similar Documents

Publication Publication Date Title
HRP20040065A2 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
US9409902B2 (en) Modulators of HEC1 activity and methods therefor
US10501433B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5295230B2 (ja) 粘液分泌の刺激剤としての３’，４’，５−トリメトキシフラボン誘導体、その方法、および上記化合物を含んでなる医薬組成物
US20130281397A1 (en) Treatment of diseases by epigenetic regulation
PT2287155E (pt) Composto de aciltioureia ou um seu sal, e sua utilização
US10245259B2 (en) Methods of treating RBP4 related diseases with triazolopyridines
US5990117A (en) Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
CN110240557A (zh) 吡咯烷酰胺衍生物及其用途
KR20140056164A (ko) 신규 푸라논 유도체
CN111072604B (zh) α-氨基酰胺衍生物及其用途
CN116963727A (zh) 用于治疗眼部病症的药剂
CN112010818A (zh) 吗啉酰胺衍生物及其用途
CN108912029A (zh) 含氮杂环酰胺衍生物及其用途
AU2004234245A1 (en) Fused pyrimidine derivative
CN115397423A (zh) 用于治疗mps1的组合疗法
JP2020189788A (ja) 睡眠誘導剤である複素環化合物
WO2023232171A1 (en) Heterocyclic compounds for the prevention and therapy of circadian rhythm disorders
JP2021017405A (ja) 色素性乾皮症及び色素性乾皮症に起因する症状の予防／改善剤
WO2018232160A1 (en) Methods of treating metabolic diseases with phenoxyethylamides
JP2022500356A (ja) セレノフェノクロメンヒドロキサム酸、調製および血管新生阻害剤としての使用
ZA200700129B (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
JP2004091483A (ja) 置換アミノ化合物およびその用途
JP2003073380A (ja) フロイソキノリン誘導体、その製造法および用途